Is the pneumonia vaccine recommended for a 21-year-old with an egg allergy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The pneumonia vaccine is not routinely recommended for a healthy 21-year-old with an egg allergy, as the standard pneumococcal vaccines are not made with egg proteins and are considered safe, but are typically recommended for adults 65 and older, or younger adults with specific medical conditions. The egg allergy itself is not a contraindication to receiving pneumococcal vaccines, as these vaccines do not contain egg proteins in their manufacturing process, unlike some influenza vaccines which may contain trace amounts of egg protein 1.

Key Considerations

  • Pneumococcal vaccines are typically recommended for adults 65 and older, or younger adults with certain medical conditions like chronic heart or lung disease, diabetes, immunocompromising conditions, cochlear implants, or those who smoke 2.
  • The standard pneumococcal vaccines (Prevnar 13/20 and Pneumovax 23) are not made with egg proteins and are considered safe for people with egg allergies 1.
  • If the 21-year-old has any of these risk factors, then vaccination would be recommended regardless of egg allergy status 3.

Vaccine Safety and Efficacy

  • The pneumococcal conjugate vaccines have shown to be highly efficacious in preventing invasive diseases in high-risk groups 4.
  • The 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed for vaccination of adults >50 years based on safety and immunogenicity data; an efficacy trial is being conducted 1.
  • Novel immunization strategies remain the only practical means to reduce significantly the remaining global mortality and morbidity due to S. pneumoniae in adults 1.

References

Research

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2013

Research

The new pneumococcal vaccine.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.